South Korea’s ambitious plan to improve corporate governance standards got a boost after the parliament voted to approve changes that will help protect the rights of minority shareholders https://t.co/OBq2Hb27ea ...

NEW YORK, July 02, 2025 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Napco Security Technologies, Inc. (NASDAQ: NSSC) breached their fiduciary duties to shareholders. According to a federal securities lawsuit, Insiders at Napco Security caused the company to misrepresent Napco’s overall expected growth and strength in the Company’s hardware division, including, among other things, confidence in Napco’s ability to achieve i ...

Core Viewpoint - Kuehn Law, PLLC is investigating potential breaches of fiduciary duties by officers and directors of NET Power Inc. related to misleading statements about Project Permian [1][2] Group 1: Allegations of Misrepresentation - Insiders at NET Power allegedly caused the company to misrepresent the likelihood of completing Project Permian on schedule, indicating it would be significantly more expensive due to supply chain issues and site-specific challenges [2] - Projections regarding the time and capital needed to complete Project Permian were deemed unrealistic, suggesting a significant negative impact on the company's business and financial results [2] - Public statements made by NET Power were materially false and misleading at all relevant times, according to the federal securities lawsuit [2] Group 2: Shareholder Actions - Shareholders who purchased NPWR shares prior to June 9, 2023, are encouraged to contact Kuehn Law for potential legal action, as there may be limited time to enforce their rights [3] - Kuehn Law offers to cover all case costs and does not charge investor clients, emphasizing the importance of shareholder participation in maintaining market integrity [4]

Core Insights - The investment approach focuses on identifying businesses with potential for long-term growth and significant terminal value generation [1] - Emphasis is placed on understanding core business economics, including competitive advantages, unit economics, reinvestment opportunities, and management quality [1] - The goal is to generate long-term free cash flow and create shareholder value through fundamental research [1] Investment Strategy - The strategy targets sectors with strong secular tailwinds, indicating a preference for industries poised for sustained growth [1] - The investor is self-educated and has been active in the investment field for 10 years, currently managing personal funds sourced from friends and family [1] - The motivation for sharing insights is to provide value to readers and receive feedback from the investment community [1]

Core Viewpoint - A class action lawsuit has been filed against Petco Health and Wellness Company, Inc. for allegedly making materially false and misleading statements regarding its business operations and prospects during the pandemic [1][3]. Summary by Relevant Sections Lawsuit Details - The lawsuit was filed in the United States District Court for the Southern District of California on behalf of all individuals and entities who purchased Petco securities between January 14, 2021, and June 5, 2025 [1]. - Investors have until August 29, 2025, to apply to be appointed as lead plaintiff in the lawsuit [1]. Allegations Against Petco - The lawsuit claims that Petco's pandemic-related growth was unsustainable and that its business model focused on premium pet food was flawed [3]. - It is alleged that the strength of Petco's differentiated product strategy was overstated [3]. - The defendants are accused of downplaying the severity of operational issues and the necessary changes to address them, which could negatively impact Petco's comparable sales [3]. - The lawsuit asserts that Petco's ability to achieve sustainable and profitable growth was overstated [3]. Contact Information - For those affected or seeking more information, contact details for Bragar Eagel & Squire, P.C. are provided, including email and phone number [4][7].

Core Viewpoint - The article discusses a class action lawsuit against Sarepta Therapeutics, alleging violations of the Securities Exchange Act of 1934 due to misleading statements regarding the safety and efficacy of its gene therapy product, ELEVIDYS, during a specified class period [1][3]. Company Overview - Sarepta Therapeutics is a commercial-stage biopharmaceutical company focused on developing therapies for Duchenne muscular dystrophy, including its gene therapy product, ELEVIDYS [2]. Allegations of the Lawsuit - The lawsuit claims that Sarepta and its executives made false or misleading statements about ELEVIDYS, including significant safety risks, inadequate trial protocols to detect severe side effects, and the potential for halting recruitment and dosing due to adverse events [3]. - Specific incidents cited include: - On March 18, 2025, a patient treated with ELEVIDYS suffered acute liver failure leading to death, causing Sarepta's stock to drop over 27% [4]. - On April 4, 2025, Sarepta disclosed that EU authorities requested a review of the death, leading to a further stock decline of over 7% [5]. - On June 15, 2025, a second patient died from acute liver failure, prompting Sarepta to suspend shipments and pause dosing, resulting in a stock price drop of over 42% [6]. - On June 24, 2025, the FDA announced an investigation into the deaths related to ELEVIDYS, causing an additional stock decline of over 8% [7]. Lead Plaintiff Process - The Private Securities Litigation Reform Act of 1995 allows investors who purchased Sarepta securities during the class period to seek appointment as lead plaintiff, representing the interests of the class [8].

Core Points - A shareholder class action lawsuit has been filed against Petco Health and Wellness Company, Inc. alleging that the company made materially false and misleading statements regarding its business and operations [1] - The lawsuit claims that Petco's pandemic-related growth was unsustainable and that its business model focused on premium pet food was overstated [1] - Defendants are accused of downplaying the severity of issues affecting Petco's business and overstating the company's ability to achieve sustainable, profitable growth [1] Legal Information - Shareholders who purchased Petco shares between January 14, 2021, and June 5, 2025, and suffered significant losses are encouraged to discuss their legal rights [2] - The deadline to request lead plaintiff status in the lawsuit is August 29, 2025 [3] - Holzer & Holzer, LLC is representing shareholders in this litigation and has a history of recovering significant amounts for investors affected by corporate misconduct [3]

Core Viewpoint - A class action lawsuit has been filed against Red Cat Holdings, Inc. for allegedly misleading investors regarding its production capacity and the value of its contracts, particularly the U.S. Army's Short Range Reconnaissance Program [1][2][3] Allegations - The complaint states that Red Cat Holdings overstated the production capacity of its Salt Lake City Facility and the overall value of the SRR Contract [2] - Kerrisdale Capital's report claims the SRR Contract is valued between $20 million and $25 million, contrary to Red Cat's representations [3] - Following the report, Red Cat's stock price dropped by $2.35 per share, or 21.54%, closing at $8.56 on January 17, 2025 [3] Class Action Participation - Shareholders interested in serving as lead plaintiffs have until July 22, 2025, to apply for this status [4] - Participation in the class action is not required to be eligible for recovery, allowing shareholders to remain absent class members if they choose [4] Company Background - Robbins LLP is noted for its focus on shareholder rights litigation, aiming to help shareholders recover losses and improve corporate governance [5]

Group 1 - A class action has been filed against Petco Health and Wellness Company, Inc. for misleading investors regarding its business prospects during the period from January 14, 2021, to June 5, 2025 [1][2] - Allegations include that Petco's pandemic-related growth was unsustainable and that the company overstated its ability to deliver sustainable, profitable growth [2] - The complaint highlights that the true scope of issues affecting Petco's business model and sales metrics was downplayed by the defendants [2] Group 2 - Shareholders may participate in the class action and can contact Robbins LLP if they wish to serve as lead plaintiff [3] - The representation in the class action is on a contingency fee basis, meaning shareholders pay no fees or expenses [4] - Robbins LLP has been dedicated to helping shareholders recover losses and improve corporate governance since 2002 [4]

Core Viewpoint - A class action lawsuit has been filed against Sarepta Therapeutics, Inc. for allegedly misleading investors regarding the safety of its gene therapy drug, ELEVIDYS, which is intended for treating Duchenne muscular dystrophy [1][2]. Allegations - The lawsuit claims that Sarepta failed to disclose significant safety risks associated with ELEVIDYS, including the inability of trial protocols to detect severe side effects and the potential for adverse events to halt recruitment and dosing in clinical trials [2]. - Specific allegations include that the severity of adverse events would attract regulatory scrutiny and increase risks surrounding the therapy's approvals [2]. Stock Price Impact - Following a safety update on March 18, 2025, which reported a patient death after ELEVIDYS treatment, Sarepta's stock price dropped by $27.81, or 27.44%, closing at $73.54 [3]. - On June 15, 2025, after disclosing a second patient death due to acute liver failure and announcing a suspension of shipments for non-ambulatory patients, the stock fell by $15.24, or 42.12%, closing at $20.91 [3]. - The FDA's investigation announcement on June 24, 2025, regarding the risk of acute liver failure led to an additional stock price decline of $1.52, or 8.01%, closing at $17.46 [4]. Class Action Participation - Shareholders interested in participating as lead plaintiffs in the class action must file a motion by August 25, 2025, although participation is not required to be eligible for recovery [5].